Zorevunersen (STK-001) demonstrates potential for disease modification, including reductions in seizures and improvements in cognition and behavior in children and adolescents with Dravet syndrome
Patients with Dravet syndrome in open-label extension studies of zorevunersen (STK-001) have durable reductions in seizure frequency and ongoing improvements in cognition and behavior
Small changes on the Vineland-3 are meaningful to caregivers of patients with Dravet syndrome
Spectral EEG analysis demonstrates decreased slow-wave activity in patients with Dravet syndrome after treatment with zorevunersen (STK-001), an antisense oligonucleotide